blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2407536

EP2407536 - ADP-ribosyl transferase fusion variant proteins [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  05.09.2014
Database last updated on 31.08.2024
Most recent event   Tooltip13.03.2020Change - lapse in a contracting state
State(s) deleted from list of lapses: TR		published on 15.04.2020  [2020/16]
Applicant(s)For all designated states
Bioaxone Biosciences Inc.
1313 s. Andrew Avenue
Fort Lauderdale, FL 33316 / US
[2012/26]
Former [2012/03]For all designated states
Bioaxone Therapeutique Inc.
Suite 200 7150 Frédérick-Banting Street
Montréal, Québec H4S 2A1 / CA
Inventor(s)01 / McKerracher, Lisa
302 2115 rue Saint-Urbain
Montréal, Québec H2X 2N1 / CA
02 / Munzer, Jon Scott
15 Round Table Road
Shrewsbury, MA 01545 / US
 [2012/03]
Representative(s)Patentanwälte Ruff, Wilhelm, Beier, Dauster & Partner mbB
Postfach 10 40 36
70035 Stuttgart / DE
[N/P]
Former [2012/03]Patentanwälte Ruff, Wilhelm, Beier, Dauster & Partner
Postfach 10 40 36
70035 Stuttgart / DE
Application number, filing date10195185.312.12.2007
[2012/03]
Priority number, dateUS2006064394022.12.2006         Original published format: US 643940
US2007080877312.06.2007         Original published format: US 808773
[2012/03]
Previously filed application, dateWO2007CA0226512.12.2007
[2012/03]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2407536
Date:18.01.2012
Language:EN
[2012/03]
Type: A9 Corrected patent application 
No.:EP2407536
Date:13.03.2013
[2013/11]
Type: B1 Patent specification 
No.:EP2407536
Date:30.10.2013
Language:EN
[2013/44]
Search report(s)(Supplementary) European search report - dispatched on:EP29.11.2011
ClassificationIPC:C12N9/10, A61K38/45, A61K47/42, A61K47/48, A61K9/19, A61P25/00, A61P35/00, A61P35/04, A61P9/00, C07K14/435, C07K19/00
[2012/03]
CPC:
C12N9/1077 (EP,US); A61K47/60 (EP,US); A61P21/00 (EP);
A61P21/02 (EP); A61P21/04 (EP); A61P25/00 (EP);
A61P25/14 (EP); A61P25/16 (EP); A61P25/28 (EP);
A61P27/02 (EP); A61P27/06 (EP); A61P3/00 (EP);
A61P31/18 (EP); A61P33/14 (EP); A61P35/00 (EP);
A61P35/04 (EP); A61P37/00 (EP); A61P39/02 (EP);
A61P9/00 (EP); A61P9/10 (EP); A61K38/00 (EP,US);
C07K2319/01 (EP,US); C07K2319/03 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2012/03]
TitleGerman:ADP-Ribosyltransferase-Fusionsproteinvarianten[2012/03]
English:ADP-ribosyl transferase fusion variant proteins[2012/03]
French:Protéines variantes de fusion d'ADP-ribosyl transférase[2012/03]
Examination procedure18.07.2012Amendment by applicant (claims and/or description)
18.07.2012Examination requested  [2012/35]
09.08.2012Despatch of a communication from the examining division (Time limit: M06)
19.02.2013Reply to a communication from the examining division
06.05.2013Communication of intention to grant the patent
16.09.2013Fee for grant paid
16.09.2013Fee for publishing/printing paid
Parent application(s)   TooltipEP07855547.1  / EP2118275
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  09.08.2012
Opposition(s)31.07.2014No opposition filed within time limit [2014/41]
Fees paidRenewal fee
15.12.2010Renewal fee patent year 03
15.12.2010Renewal fee patent year 04
14.12.2011Renewal fee patent year 05
18.12.2012Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipBE30.10.2013
BG30.10.2013
CY30.10.2013
CZ30.10.2013
EE30.10.2013
LT30.10.2013
LV30.10.2013
MT30.10.2013
PL30.10.2013
RO30.10.2013
SI30.10.2013
SK30.10.2013
GR31.01.2014
IS28.02.2014
PT28.02.2014
[2020/16]
Former [2020/15]BE30.10.2013
BG30.10.2013
CY30.10.2013
CZ30.10.2013
EE30.10.2013
LT30.10.2013
LV30.10.2013
MT30.10.2013
PL30.10.2013
RO30.10.2013
SI30.10.2013
SK30.10.2013
TR30.10.2013
GR31.01.2014
IS28.02.2014
PT28.02.2014
Former [2019/29]BE30.10.2013
BG30.10.2013
CY30.10.2013
CZ30.10.2013
EE30.10.2013
LT30.10.2013
LV30.10.2013
MT30.10.2013
PL30.10.2013
RO30.10.2013
SI30.10.2013
SK30.10.2013
GR31.01.2014
IS28.02.2014
PT28.02.2014
Former [2016/28]BE30.10.2013
BG30.10.2013
CY30.10.2013
CZ30.10.2013
EE30.10.2013
LT30.10.2013
LV30.10.2013
MT30.10.2013
PL30.10.2013
RO30.10.2013
SI30.10.2013
SK30.10.2013
TR30.10.2013
GR31.01.2014
IS28.02.2014
PT28.02.2014
Former [2015/41]BE30.10.2013
BG30.10.2013
CY30.10.2013
CZ30.10.2013
EE30.10.2013
GR30.10.2013
LT30.10.2013
LV30.10.2013
MT30.10.2013
PL30.10.2013
RO30.10.2013
SI30.10.2013
SK30.10.2013
TR30.10.2013
IS28.02.2014
PT28.02.2014
Former [2015/38]BE30.10.2013
BG30.10.2013
CY30.10.2013
CZ30.10.2013
EE30.10.2013
GR30.10.2013
LT30.10.2013
LV30.10.2013
PL30.10.2013
RO30.10.2013
SI30.10.2013
SK30.10.2013
TR30.10.2013
IS28.02.2014
PT28.02.2014
Former [2015/35]BE30.10.2013
BG30.10.2013
CY30.10.2013
CZ30.10.2013
EE30.10.2013
LT30.10.2013
LV30.10.2013
PL30.10.2013
RO30.10.2013
SI30.10.2013
SK30.10.2013
TR30.10.2013
IS28.02.2014
PT28.02.2014
Former [2015/32]BE30.10.2013
CY30.10.2013
CZ30.10.2013
EE30.10.2013
LT30.10.2013
LV30.10.2013
PL30.10.2013
RO30.10.2013
SI30.10.2013
SK30.10.2013
TR30.10.2013
IS28.02.2014
PT28.02.2014
Former [2015/14]BE30.10.2013
CY30.10.2013
CZ30.10.2013
EE30.10.2013
LT30.10.2013
LV30.10.2013
PL30.10.2013
RO30.10.2013
SI30.10.2013
SK30.10.2013
IS28.02.2014
PT28.02.2014
Former [2014/37]BE30.10.2013
CY30.10.2013
CZ30.10.2013
EE30.10.2013
LT30.10.2013
LV30.10.2013
PL30.10.2013
RO30.10.2013
SK30.10.2013
IS28.02.2014
PT28.02.2014
Former [2014/36]BE30.10.2013
CY30.10.2013
EE30.10.2013
LT30.10.2013
LV30.10.2013
IS28.02.2014
PT28.02.2014
Former [2014/28]BE30.10.2013
CY30.10.2013
LT30.10.2013
LV30.10.2013
IS28.02.2014
PT28.02.2014
Former [2014/26]BE30.10.2013
CY30.10.2013
LT30.10.2013
LV30.10.2013
IS28.02.2014
Former [2014/25]BE30.10.2013
LT30.10.2013
LV30.10.2013
IS28.02.2014
Former [2014/23]BE30.10.2013
LT30.10.2013
IS28.02.2014
Former [2014/20]LT30.10.2013
Documents cited:Search[X]WO02083179  (BIOAXONE THERAPEUTIQUE INC [CA]) [X] 1-17 * the whole document *;
 [X]WO2005030248  (BIOAXONE THERAPEUTIQUE INC [CA], et al) [X] 1-17 * the whole document *;
 [X]  - "Clostridium botulinum C3APLT protein in a pET vector.", Geneseq, (20030324), Database accession no. AAE32059, URL: EBI, XP002663653 [X] 1-17 * the whole document *
by applicantCA2304981
 CA2300878
 CA2325842
 US5707643
 US5443505
 US5632984
 US5770589
 US5767079
 US5273530
 US6397849
 US6299895
 US5399163
 US5383851
 US5312335
 US5064413
 US4941880
 US4790824
 US4596556
 US4487603
 US4486194
 US4447233
 US4447224
 US4439196
 US4475196
 US7141428
 USRE39298E
 USRE39321E
 US4427650
 US4427651
 US4414976
 US4640834
 US5290552
 US5607694
 US5714370
 US5750657
 US5773418
 US5962405
 US5962420
 US6117425
 US6162241
 US6262236
 US6780411
 US2005271646
 EP0804257
 USRE39299E
    - CHEN ET AL., PNAS, (2002), vol. 99, pages 9031 - 9036
    - DILLON, FEIG, METHODS IN ENZYMOLOGY: SMALL GTPASES AND THEIR REGULATORS PART. B, (1995), vol. 256, pages 174 - 184
    - CLARK ET AL., NATURE, (2000), vol. 406, pages 532 - 535
    - UEHATA ET AL., NATURE, (1997), vol. 389, page 990
    - LEE ET AL., FASEB J., vol. 15, pages 1886 - 1884
    - WILDE ET AL., J. BIOL. CHEM., (2000), vol. 275, page 16478
    - LEHMANN ET AL., J. NEUROSCI., (1999), vol. 19, pages 7537 - 7547
    - RIDLEY, HALL, CELL, (1992), vol. 70, pages 389 - 399
    - BOQUET ET AL., METH. ENZYMOL., (1995), vol. 256, pages 297 - 306
    - BARTHE ET AL., INFECTION AND IMMUNITY, (1998), vol. 66, page 1364
    - QUIGLEY HA, "Glaucoma: Macrocosm to Microcosm The Friedenwald Lecture", INVEST. OPHTHALMOL. VIS. SCI., (2005), vol. 46, pages 2663 - 2670
    - LEE DA, HIGGINBOTHAM EJ, "Glaucoma and its treatment: a review", AM. J. HEALTH-SYST. PHARM., (2005), vol. 62, pages 691 - 600
    - ANDERSON DR, "Collaborative Normal Tension Glaucoma Study", CURR. OPIN. OPHTHALMOL., (2003), vol. 14, pages 86 - 90
    - VAN'T VEER ET AL., NATURE, (2002), vol. 415, pages 530 - 536
    - FISCHER ET AL., J. NEUROSCIENCE, (2004), vol. 24, pages 8726 - 2740
    - SMITH, WATERMAN, AD. APPL.MATH., (1981), vol. 2, pages 482 - 489
    - NEEDLEMAN, WUNSCH, J.MOL.BIOL., (1970), vol. 48, pages 443 - 453
    - JANKNECHT ET AL., PROC. NATL. ACAD. SCI., (1981), vol. 88, page 8972
    - WINTON ET AL., J BIOL CHEM, (2002), vol. 277, pages 32820 - 32829
    - LASKO, MCKERRACHER, METHODS ENZYMOL., (2006), vol. 406, pages 512 - 520
    - UNOKI, LAVAIL, INVEST OPTHALMOL VIS. SCI., (1994), vol. 35, page 907
    - MORRISON ET AL., EXP. EYE RES., (1997), vol. 64, pages 85 - 96
    - MORRISON ET AL., PROGRESS IN RETINAL AND EYE RESEARCH, (2005), pages 217 - 240
    - FAKTOROVICH ET AL., NATURE, (1990), vol. 347, page 83
    - LAVAIL ET AL., PNAS USA, (1992), vol. 89, page 11249
    - ERICKSON ET AL., J STRUCT. BIOL., (1992), vol. 108, page 148
    - CAFFE ET AL., CURR. EYE RES., (1993), vol. 12, page 719
    - BERTRAND ET AL., J NEUROSCI, (2005), vol. 25, pages 1113 - 1121
    - DERGHAM ET AL., J NEUROSCI, (2002), vol. 22, pages 6570 - 6577
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.